TV Networks Are Underestimating Apple's Power
- Shares of Apple Inc. (NASDAQ: AAPL) have declined 10.71 percent year-to-date, falling to a low of $93.78 on February 11.
- JPMorgan’s Rod Hall has maintained a Buy rating on the company, with a price target of $141.
- The Wall Street Journal reported that the company is developing its very first TV series, called “Vital Signs” and expected to be available only on Apple Music.
Analyst Rod Hall believes that “the Networks and content owners are underestimating the power that Apple has to rewrite the content ecosystem including producing their own original content and potentially bidding for sports rights.”
“Vital Signs” is a six-episode series that will star Dr. Dre, the hip-hop producer who joined Apple as a senior executive in 2014, and founded Beats Electronics and Beats Music.
See Also: Dr. Dre TV Show 'Vtial Signs' Coming To Apple
According to Apple’s Senior V.P., Eddy Cue, the company has crossed the 11 million subscriber mark, along with 782 million iCloud users.
India Tech Center
Apple is also reportedly set to open a $25 million offshore technology development facility in India. This will be the company’s first tech development center outside the US and is expected to create 4,500 jobs for Hyderabad, India.
According to the JPMorgan report, “Apple will initially open its innovation center in June and launch fully fledged operations by the end of this year. It plans to develop maps and make them available in its iPhones and Mac systems.”
In addition, there have been reports that the company is planning to launch a new 4-inch iPhone, the iPhone 5se, along with the new iPad Air, on March 18.
Latest Ratings for AAPL
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Barclays | Maintains | Equal-Weight | |
Feb 2022 | Tigress Financial | Maintains | Strong Buy | |
Jan 2022 | Credit Suisse | Maintains | Neutral |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Dr. Dre JPMorganAnalyst Color Long Ideas Reiteration Analyst Ratings Tech Trading Ideas Best of Benzinga